Pain

Summary : Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria In this Phase 3 trial, Dupixent…

SUMMARY: The U.S. Food and Drug Administration today authorized marketing of EaseVRx, a prescription-use immersive virtual reality (VR) system that uses cognitive…

Keypoints Med-X, Inc. announced that the Company received Patent No. 11,147,266 B2 for its Nature-Cide Insecticidal Soil formulation. Med-X’s goal is to…